Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01125761
Other study ID # DECEMS21209
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date November 2010
Est. completion date November 2010

Study information

Verified date November 2022
Source Azidus Brasil
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Considering the pathogenesis of several allergic skin diseases to be investigated in this study as well as the pharmacodynamic mechanisms of the association of dexamethasone and clemastine fumarate, it is believed that the components of topical medication may act synergistically in the reduction of signs and symptoms of the diseases in question. Therefore it is expected that the association promotes results significantly superior to dexamethasone alone.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 2010
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who sign the Deed of Consent (IC) in two ways, by his own free will, agreeing with all study procedures; - Patients older than 18 years, any ethnicity, class or social group, regardless of sex; - Patients with pictures of dermatoses acute, subacute or chronic, of inflammatory origin and / or allergic, to which it is recommended the use of drugs under investigation topically, such as: - atopic dermatitis, - prurigo, - primary contact dermatitis or allergic - urticaria, - pharmacodermic, - allergic vasculitis, - dyshidrosis, Exclusion Criteria: - Patients being treated with antibiotics; - Participation in clinical trials in the 12 months preceding the survey; - Current treatment with immunosuppressants (eg, cyclosporine or methotrexate); - Current treatment with phototherapy (UVA, UVB, PUVA and lasers); - Use of systemic corticosteroids at inclusion visit or within 15 days prior to inclusion; - Topical treatments at the site of acne in the 15 days preceding the visit of inclusion; - Presence of any skin condition in areas affected by acne that hamper the evolutionary analysis of the lesion; - Presence of secondary infections at the site of treatment, diagnosed clinically; - Presence of other eczematous picture, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome Wiskott-Aldrich; - Pregnant or lactating women; - Chronic alcoholism; - Patients with a history of hypersensitivity to any component of the formulas of the products under investigation; - Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study; - Allergic Dermatosis of moderate or severe that, according to the investigator, is not justified topical.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
dexamethasone 0.5 mg and 1.0 mg clemastine cream
The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
Dexamethasone 0,5 mg cream
The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.

Locations

Country Name City State
Brazil LAL Clinica Pesquisa e Desenvolvimento Ltda Valinhos São Paulo
Brazil LAL Clínica Pesquisa e Desenvolvimento Ltda Valinhos São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Azidus Brasil

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Through clinical examinations, evaluating the efficacy of the cream composed by 0.5 mg dexamethasone and clemastine 1mg compared with the cream of 0.5 mg dexamethasone in improving the signs and symptoms associated with allergic dermatitis. 14 days
Secondary Improvement of the erythema associated with allergic dermatitis. 14 days
Secondary Improvement of the edema associated with allergic dermatitis. 14 days
Secondary Improvement of the extension of lesion associated with allergic dermatitis. 14 days
Secondary Evaluate, through clinical examinations, the effectiveness of the drug association in reducing excoriation associated with allergic dermatitis. 14 days
Secondary Evaluate, through clinical examinations, the effectiveness of the drug association in reducing exudation associated with allergic dermatitis. 14 dyas
Secondary Evaluate, through clinical examinations, the effectiveness of the drug association in reducing of scabbing associated with allergic dermatitis. 14 days
Secondary Evaluate, through clinical examinations, the effectiveness of the drug association in reducing of lichenification associated with allergic dermatitis. 14 days
Secondary Evaluate the safety of the formulations in relation to the occurrence, type, frequency and intensity of adverse events during treatment. 14 days
See also
  Status Clinical Trial Phase
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Recruiting NCT01012453 - A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema N/A
Completed NCT00375713 - Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema Phase 3
Completed NCT00001150 - Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers N/A
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Withdrawn NCT04154033 - Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone Phase 2
Completed NCT02979210 - Infant Fecal Insult Study N/A
Completed NCT02615912 - A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants N/A
Withdrawn NCT00746382 - A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM) Phase 2
Terminated NCT00176956 - Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients Phase 3
Completed NCT05001139 - Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam N/A
Completed NCT00801502 - Salmon in Pregnancy Study N/A
Completed NCT00005781 - Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles N/A
Completed NCT05324618 - Tacrolimus Versus Hydrocortisone in Atopic Dermatitis Phase 4
Completed NCT04826471 - Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam N/A
Recruiting NCT06436183 - A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis Phase 2
Recruiting NCT05891743 - Prevalence of Skin Sensitization and Dermatitis Among Epoxy-exposed Workers in the Wind Turbine Industry.